Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
China is pushing to accelerate novel drug reviews. Photo: Shutterstock
China’s private sector

‘Historic breakthrough’: China approves novel drug ahead of US, Japan and Europe

Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

Banking & finance

Healthcare IPO wave: US biotech firm picks Hong Kong over Nasdaq for listing

China’s private sector

‘Systemic leap’: China’s drug innovation push yields bumper crop

videocam
Banking & finance

Mainland funds boost stakes in Hong Kong-listed biotech amid value dislocation

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.

Hong Kong’s skyline is seen from The Peak on June 1. Photo: Karma Lo
China manufacturing

The next rare earths? Why US fears another Chinese manufacturing advantage

China’s production of drug inputs has boomed in recent years, increasing market share and prompting fears of weaponisation in Washington.

videocam
25
China’s private sector

Europe beckons: can Chinese medical device makers thrive amid trade barriers?

Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.

Advertisement
Advertisement
Advertisement
China’s private sector

Can AI collaborations power China’s next wave of blockbuster drug deals?

China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.

A pharmaceutical manufacturing line. Photo: Shutterstock
Hong Kong economy

Opinion | Hong Kong can be the Asia-Pacific’s longevity hub

City has unique conditions to be the premier regional hub for longevity research, clinical trials, regulatory approval and capital scaling.

videocam
China’s private sector

China’s biotech boom: RAS-targeted drugs challenge US dominance

The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.

China’s private sector

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

videocam
Industry insiders say AI-powered drug-design tools have the potential to shorten development timelines from years to as few as 18 months. Photo: Shutterstock
China’s private sector

Hong Kong draws royalties giant as mainland China biotech licensing heats up

Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.

Royalty Pharma is scouting the Asia-Pacific region for innovative biotechnology start-ups with late-stage pharmaceutical pipelines. Photo: Shutterstock
China’s private sector

China’s first AI-powered cancer vaccine production line set to launch in Beijing

Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.

China’s private sector

China is fretting over a demographic crisis – but what companies might benefit?

Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle.

China’s private sector

China’s biotech boom: record 5,215 clinical drug trials reported in 2025

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in Washington.

Cancer research being conducted in a modern lab. Cancer treatments remained the top focus of the record 5,215 clinical drug trials in China last year. Photo: Shutterstock
China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
US-China relations

Biotech firm WuXi sues US over allegations it supports China’s military

The company says it suffered substantial reputational and operational harm after being placed on a Pentagon blacklist.

videocam
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

Advertisement
Advertisement
Advertisement
China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

Growing collaboration between multinational drug makers and Chinese companies not expected to slow after US move.

The cost advantages of Chinese pharmaceuticals mean they still appeal to multinational drug makers despite US security concerns. Photo: TNS
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

China’s private sector

With AI able to predict disease, can we treat ageing like a ‘bug’ in the system?

AI is transforming longevity as companies like METiS TechBio and Human Longevity use algorithms to combat ageing and predict health risks.

Hong Kong stock market

GenScript rally underscores China’s rise in cancer drug innovation

The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China’s biotechnology sector by US lawmakers.

The Hong Kong-listed biotech company rose as much as 29 per cent after rejecting suggestions by US lawmakers it poses a national security risk. Photo: Getty Images
Science

Biomedicine | China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM

With the most cases of the two leading neurodegenerative diseases, and affected population rising as country ages, China needs to find new treatments.

China steps up Alzheimer’s, Parkinson’s drug push, looks to TCM
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

Biomedicine: Industry Trends

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
Science

Chinese team uses supercomputer to cut drug screening time from years to seconds

AI platform that can screen vast library of chemical compounds opens up new frontiers in fight against cancer and infectious diseases.

videocam
Innovative drug research and development typically takes more than 10 years to yield results. Photo: Shutterstock
China’s private sector

China’s biotech boom drives surge in home-grown innovative drug approvals

Domestic firms dominate China’s drug approvals amid jump in spending and out-licensing deals as regulator speeds path to market.

Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026. Photo: Getty Images
China’s private sector

Insilico, US partner to build AI models predicting disease decades ahead

Tie-up combines Hong Kong-listed Insilico Medicine’s algorithms with Human Longevity’s genomic data to advance personalised health research.

Banking & finance

Hong Kong-listed firm uses AI to make nano-rockets to deliver life-saving drugs

METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical industry.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement